학술논문
Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial
Document Type
Article
Author
Source
In The Lancet Oncology November 2014 15(12):1351-1360
Subject
Language
ISSN
1470-2045